<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bradykinin B2 receptor-deleted mice (Bdkrb2(-/-)) have delayed carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> times and prolonged tail <z:mp ids='MP_0001914'>bleeding</z:mp> time resulting from elevated <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> (<z:chebi fb="0" ids="48432">AngII</z:chebi>) and angiotensin receptor 2 (AT2R) producing increased plasma nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) and prostacyclin </plain></SENT>
<SENT sid="1" pm="."><plain>Bdkrb2(-/-) also have elevated plasma angiotensin-(1-7) and <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> and protein for its receptor Mas </plain></SENT>
<SENT sid="2" pm="."><plain>Blockade of Mas with its <z:chebi fb="68" ids="48706">antagonist</z:chebi> A-779 in Bdkrb2(-/-) shortens <z:mp ids='MP_0005048'>thrombosis</z:mp> times (58 ± 4 minutes to 38 ± 4 minutes) and <z:mp ids='MP_0001914'>bleeding</z:mp> times (170 ± 13 seconds to 88 ± 8 seconds) and lowers plasma nitrate (22 ± 4 μM to 15 ± 5 μM), and 6-keto-PGF1α (259 ± 103 pg/mL to 132 ± 58 pg/mL) </plain></SENT>
<SENT sid="3" pm="."><plain>Bdkrb2(-/-) platelets express increased NO, <z:chebi fb="0" ids="16750">guanosine</z:chebi> 3',5'-cyclic monophosphate, and cyclic <z:chebi fb="3" ids="16335">adenosine</z:chebi> monophosphate with reduced spreading on collagen, collagen <z:chebi fb="7" ids="16670">peptide</z:chebi> GFOGER, or fibrinogen </plain></SENT>
<SENT sid="4" pm="."><plain>In vivo A-779 or combined L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> and <z:chebi fb="0" ids="44445">nimesulide</z:chebi> treatment corrects it </plain></SENT>
<SENT sid="5" pm="."><plain>Bdkrb2(-/-) platelets have reduced collagen-related <z:chebi fb="7" ids="16670">peptide</z:chebi>-induced integrin α2bβ3 activation and P-selectin expression that are partially corrected by in vivo A-779, <z:chebi fb="0" ids="44445">nimesulide</z:chebi>, or L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Bone marrow transplantations show that the platelet phenotype and <z:mp ids='MP_0005048'>thrombosis</z:mp> time depends on the host rather than donor bone marrow progenitors </plain></SENT>
<SENT sid="7" pm="."><plain>Transplantation of <z:mp ids='MP_0002169'>wild-type</z:mp> bone marrow into Bdkrb2(-/-) hosts produces platelets with a spreading defect and delayed <z:mp ids='MP_0005048'>thrombosis</z:mp> times </plain></SENT>
<SENT sid="8" pm="."><plain>In Bdkrb2(-/-), combined AT2R and Mas overexpression produce elevated plasma prostacyclin and NO leading to acquired platelet function defects and <z:mp ids='MP_0005048'>thrombosis</z:mp> delay </plain></SENT>
</text></document>